[
  {
    "ts": null,
    "headline": "Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?",
    "summary": "DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.",
    "url": "https://finnhub.io/api/news?id=9fca1e0631e5227e804cfb9ae4c46338e27efffd032bcbeaf807ddb01b4b8b56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758547680,
      "headline": "Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?",
      "id": 136851585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.",
      "url": "https://finnhub.io/api/news?id=9fca1e0631e5227e804cfb9ae4c46338e27efffd032bcbeaf807ddb01b4b8b56"
    }
  },
  {
    "ts": null,
    "headline": "Is Quest Diagnostics Stock Underperforming the Dow?",
    "summary": "Although Quest Diagnostics has underperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=724f6904fc528ea855b923a29e4e3c03b634ae2c4b61754105ad1368aa5a5e2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758545398,
      "headline": "Is Quest Diagnostics Stock Underperforming the Dow?",
      "id": 136851828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Although Quest Diagnostics has underperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=724f6904fc528ea855b923a29e4e3c03b634ae2c4b61754105ad1368aa5a5e2e"
    }
  },
  {
    "ts": null,
    "headline": "Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer",
    "summary": "Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer (NSCLC). Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensi",
    "url": "https://finnhub.io/api/news?id=971b3fa5a2ead23234fcf745101987f52a49b12f54b841ee16bb88db1394eb16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758542820,
      "headline": "Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer",
      "id": 136851829,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer (NSCLC). Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensi",
      "url": "https://finnhub.io/api/news?id=971b3fa5a2ead23234fcf745101987f52a49b12f54b841ee16bb88db1394eb16"
    }
  }
]